Marisa Wexler, MS,  senior science writer—

A new triple-combination CFTR modulator therapy — vanzacaftor, tezacaftor, and deutivacaftor — has been approved by the U.S. Food and Drug Administration (FDA). The therapy, which developer Vertex Pharmaceuticals will market under the name Alyftrek, is indicated for cystic fibrosis (CF) in patients 6 and older who carry…

Infection with an airway bacterium called Haemophilus influenzae isn’t linked with worse lung health outcomes among adults with cystic fibrosis (CF), a study suggests. “Our study is the first to specifically dissect the natural history and consequences of H. influenzae infection in adult [people with] CF,” the researchers wrote. The…

A young man with cystic fibrosis (CF) successfully underwent a heart transplant, according to a first-of-its kind report described by researchers, who said the man’s heart issues arose as a rare complication of CF itself. The patient’s experience was described in the paper, “Isolated heart transplantation…

The Cystic Fibrosis Foundation is investing up to $15 million in Recode Therapeutics to help spur the development of new gene-editing medicines for people with cystic fibrosis (CF) who don’t have effective treatment options. “We are grateful to the CF Foundation for their ongoing support of our…

A Phase 1/2 clinical trial testing the inhaled gene therapy SP-101 in adults with cystic fibrosis (CF) has begun dosing, and is still recruiting participants, according to its developer Spirovant Sciences. The trial, called SAAVe (NCT06526923), aims to enroll 15 CF patients, ages 18 to 65. To…

Researchers have created a new technology to measure the thickness of mucus in the airways, which could aid in monitoring for cystic fibrosis (CF) and other diseases that affect the lungs. The team, led by scientists at Vanderbilt University in Tennessee, described the technology in the study, “…

Bonnie Ramsey, MD, a pediatrician and researcher who dedicated her career to advancing care for cystic fibrosis (CF), has been selected as the recipient of the 2025 American Pediatric Society (APS) John Howland Award. The APS has been giving this award since the early 1950s to recognize healthcare workers…

The cystic fibrosis (CF) treatment Trikafta leads to changes in airway cell gene expression, or activity, that may help fend off bacterial infections and lessen lung damage, researchers report. “This study identifies mechanisms through which ETI [Trikafta] is likely to improve antibacterial function, reduce lung damage, and reduce…

Treatment with Trikafta triggered diabetes remission in four people with cystic fibrosis (CF) at a center in Australia, with each of these patients experiencing complete resolution of CF-related diabetes, or CFRD, after starting on the approved triple therapy. In all four cases, the patients were able to stop…

A study will explore why some people with cystic fibrosis (CF) respond better to Trikafta than others. The five-year study, led by Arkansas Children’s Research Institute, is being funded through a $2.9 million grant from the National Institutes of Health (NIH). The project is being led by Jennifer…